Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abraxis BioScience, Inc.
Abraxis BioScience Reports 2008 Fourth Quarter and Full-Year Financial Results
March 21st, 2009
Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, reported financial results for the fourth quarter and full year ended December 31, 2008. Fourth Quarter 2008 Highlights Net revenue increased 1.5 percent to $92.2 million, compared with $90.8 million for the prior year period. Revenue from sales of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the fourth quarter of 2008 was $89.8 million, compared with $88.8 million for the same period in 2007. Net revenue included recognition of revenue of $9.9 million initially deferred relating to the co-promotion agreement with AstraZeneca and license agreements with Taiho...
Source: Law & Health Weekly (2009-03-21)
|
